Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Dual PI3K/mTOR inhibitor PKI-402 suppresses the growth of ovarian cancer cells by degradation of Mcl-1 through autophagy.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie - 1 Sept 2020

Hu Xiaoqing, Xia Meihui, Wang Jiabin, Yu Huimei, Chai Jiannan, Zhang Zejun, Sun Yupei, Su Jing, Sun Liankun

Abstract excerpt

The phosphoinositide 3-kinase (PI3K) /AKT/mammalian target of rapamycin (mTOR) signaling pathway is frequently mutated in cancers, leading to increased cell proliferation, migration, and chemoresistance. Currently, a number of small molecule inhibitors of the PI3K/AKT/mTOR signaling pathway have been assessed in preclinical and clinical studies. It has been found that dual PI3K/mTOR inhibitors may inhibit cell...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Ovarian Epithelial
Share to Class I Phosphatidylinositol 3-Kinases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Myeloid Cell Leukemia Sequence 1 Protein

Share to Phenylurea Compounds

Share to Phosphoinositide-3 Kinase Inhibitors

Share to Proteolysis

Share to Sequestosome-1 Protein

Share to TOR Serine-Threonine Kinases

Source

Identifiers

PMID: 32585451
DOI: 10.1016/j.biopha.2020.110397

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Dual PI3K/mTOR inhibitor PKI-402 suppresses the growth of ovarian cancer cells by degradation of Mcl-1 through autophagy.PMID 32585451Read ↗

The importance of the PI3K/AKT/MTOR pathway in the progression of ovarian cancer.Semantic proximity Read ↗

PI3K/Akt/mTOR Pathway and Its Role in Cancer Therapeutics: Are We Making Headway?Semantic proximity Read ↗

Recent development in targeting PI3K-Akt-mTOR signaling for anticancer therapeutic strategies.Semantic proximity Read ↗

Targeting the PI3K/AKT/mTOR/NFkB Axis in Ovarian CancerSemantic proximity Read ↗

Targeting the PI3K/AKT/mTOR and RAF/MEK/ERK pathways for cancer therapySemantic proximity Read ↗

Targeting PI3K in cancer: mechanisms and advances in clinical trialsSemantic proximity Read ↗

Targeting mTOR as a Cancer Therapy: Recent Advances in Natural Bioactive Compounds and ImmunotherapySemantic proximity Read ↗

Characterization of TP53 and PI3K signaling pathways as molecular targets in gynecologic malignancies.Semantic proximity Read ↗

Inhibition of apoptosis through AKT-mTOR pathway in ovarian cancer and renal cancerSemantic proximity Read ↗

SHCBP1 promotes cisplatin resistance of ovarian cancer through AKT/mTOR/Autophagy pathwaySemantic proximity Read ↗

Research progress on the PI3K/AKT signaling pathway in gynecological cancer (Review)Semantic proximity Read ↗

PINK1-PTEN axis promotes metastasis and chemoresistance in ovarian cancer via non-canonical pathwaySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.